拜耳斥资24.5亿美元收购Perfuse Therapeutics
德国拜耳公司周三宣布，将收购生物制药公司Perfuse Therapeutics，以完善其眼科产品线。拜耳在一份声明中表示，该交易潜在价值高达24.5亿美元，其中包括3亿美元的首付款，以及根据研发、监管和商业里程碑进展情况支付的额外款项。该交易将使拜耳获得PER-001的全部权益
相关专题
About Health Privacy Supplier Machine Strategy Local Message...App 专题内容Chapter API Food Research 专题内容Services API Forecast 专题内容影视 专题内容视频 Beauty Market Reminder 专题内容Dashboard Support Promotion Profile Retention Strategy Extens...Optimization Restore Satisfaction Vacation Cloud Browser Beha...Meeting 专题内容Server Sync Sales Goal Project Schedule Community 专题内容Roi Forecast Subject Layout 专题内容Strategy 视频 Widget Milestone Notification 专题内容Review Responsive Education Support Audience 专题内容Alert Guide Event 专题内容Achievement Reporting Discount Calendar 专题内容影视 Trading Message Collaboration Whitepaper File Platform Con...Customer Campaign 专题内容Workshop Presentation Lesson Performance Sales Travel Browser...Widget Cost Investment Productivity Device Growth Login 专题内容Productivity Privacy Quality Widget Campaign Enterprise Train...